ENDPOINTS NEWS6h
At least six drug­mak­ers say they will par­tic­i­pate in round two of IRA ne­go­ti­a­tions
Half of drugmakers join Medicare price talks, including Amgen, Boehringer Ingelheim, AstraZeneca, Astellas, Bristol Myers ...
ENDPOINTS NEWS13h
Bridge­Bio on­col­o­gy spin­out to go pub­lic via com­bi­na­tion with SPAC from Cor­morant and Bi­hua Chen
BridgeBio Oncology Therapeutics to go public via merger with Helix Acquisition Corp. II SPAC, led by Bihua Chen's Cormorant, ...
ENDPOINTS NEWS8h
CHMP rec­om­mends Re­gen­eron, No­var­tis drugs that still await FDA ap­proval
CHMP recommends approval of Regeneron's Lynozyfic, Krystal's Vyjuvek, Accord's trabectedin, Takeda's Deqsiga, and 16 label ...
ENDPOINTS NEWS14h
Trump’s science crackdown hits rare disease medicine: ‘We need to sit down with Elon Musk’
Jill Wood had pinned her hopes on a little-known federal program to fund her son’s gene therapy. The initiative, which awards ...
ENDPOINTS NEWS9h
In­fec­tious dis­ease doc­tors con­sid­er 'mi­ni-ACIP' if RFK erodes CDC vac­cine pan­el
Infectious disease professionals, bracing for an overhaul of the CDC's vaccine advisory group, are in discussions to stand up ...
ENDPOINTS NEWS10h
Prax­is says its es­sen­tial tremor drug failed a Phase 3 read­out but plans to com­plete study
Praxis reported that its lead small molecule program failed a Phase 3 study on Friday morning, sending its stock price down ...
ENDPOINTS NEWS14h
Pfiz­er vet William Pao’s next ven­ture; Sanofi’s com­pu­ta­tion­al sci­ence ex­ec leaves
William Pao, former Roche R&D leader and Pfizer CDO, now leads Revelio Therapeutics (formerly Launchpad) as CEO, joins ...
ENDPOINTS NEWS1d
HHS’ vac­cine in­jury pan­el in lim­bo af­ter month­long meet­ing de­lay
More than a month after its most recent scheduled meeting was postponed, a panel advising the government on a federal ...
ENDPOINTS NEWS1d
Phar­ma-backed Mis­sion Ther­a­peu­tics stops pre­clin­i­cal op­er­a­tions, fo­cus­es on two clin­i­cal as­sets
Clinical-stage biotech Mission Therapeutics is closing its preclinical laboratory operations in Cambridge, UK, a spokesperson ...
ENDPOINTS NEWS1d
Kally­ope qui­et­ly re­ports Phase 2 obe­si­ty da­ta, be­gins mid-stage mi­graine tri­al
Kallyope's Phase 2 obesity trial shows K-757 and K-833 combo achieved 2.9% weight loss vs 0.2% for placebo. Results fall ...
ENDPOINTS NEWS1d
Can Bill An­der­son save Bay­er?
Something changed for Bill Anderson when he turned 50. He was ascending the ranks of Roche’s Genentech, but the Texas native ...
ENDPOINTS NEWS1d
Start­up work­ing on oral an­ti­bod­ies shares ear­ly ul­cer­a­tive col­i­tis da­ta
Sorriso Pharmaceuticals presents Phase 1b data for SOR102, an oral bispecific antibody for IBD, showing 40% endoscopic ...